Looking for a Post-Doc
We seek for an above-average dedicated person with documented postdoctoral experience enabling her/him to lead a project group. The employment ideally starts in July ’19 and initially runs until May 2022 (TV-L E13; 6 months probation), but candidates with a genuine long-term interest to pursue an academic career towards ‘Habilitation’ are desired for an envisioned prolongation. The host laboratory is affiliated with the local CECAD and the CMMC (PI Dr. M. Herling) and offers a versatile profile in competitive projects.
Here you find further informations for applicants
Postet on July 19, 2019Consensus guidelines for T-PLL published
Although T-cell prolymphocytic leukemia had already been recognized being distinct from CLL in 1976, until today it has been managed according to criteria for CLL as described by the international workshop on CLL (IWCLL). The T-PLL International Study group (TPLL-ISG) has now set up a first consensus paper defining guidelines for the diagnosis, treatment and response evaluation of T-PLL. These guidelines will provide a basis for clinical decision making and will help to compare results from clinical trials in T-PLL.
Click here to read the article
Postet on July 15, 2019ERANET-PLL approved
The project, “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia“, was granted funding within the European ERA-net TRANSCAN 2 initiative (Horizon 2020).
The project is a cooperation of five European research groups from Austria, France and Germany, coordinated by Dr. Marco Herling (University Hospital of Cologne). It focuses on the development of new tools to predict individual in vitro drug sensitivities and synergies in the rare entity of T-cell prolymphocytic leukemia and implementation of these into the clinics.
Overall, the project is funded with 1.5 million euros.
For more details visit:
https://www.transcanfp7.eu/index.php/abstract/eranet-pll.html
Postet on July 5, 2019
EU-project funded
The project “Novel individualized therapies in JAK/STAT driven T-cell malignancies” (Acronym: JAKSTAT-Target) aims to investigate the role of the JAK STAT pathway in mature T-cell lymphomas and to detect potent drugs and drug synergisms targeting this pathway.
The consortium of six research groups from Cologne (Marco Herling), Helsinki (Satu Mustjoki, Tero Aittokallio), Toronto (Patrick Gunning, Benjamin Haibe-Kains), Vienna (Heidi Neubauer), will mainly focus on the entities of T-cell prolymphocytic leukemia (T-PLL) and T-cell large granular lymphocyte leukemia (T-LGL), both showing a high incidence of missense mutations in JAK STAT pathway genes.
The consortium led by Satu Mustjoki will receive €1,562,000 in ERA PerMed funding, of which €300,000 is allocated to the group in Cologne.
The consortium will ultimately integrate drug screen data into clinical trials and implement machine learning algorithms to predict synergistic effects from genomic, clinical and in vitro drug sensitivity data.
For more details visit:
http://www.erapermed.eu/wp-content/uploads/2019/01/ERAPerMed-9-1-19-HR.pdf
Postet on April 30, 2019
